Adlai Nortye

Adlai Nortye

Pioneering the future of oncology with innovative drug development across the globe.

Founded 2016 51-200 employees Post-IPO Equity Total: $293.00M Biotechnology, Health Care +1

Adlai Nortye is revolutionizing the landscape of oncology through pioneering innovative drug development worldwide. Founded in 2016, the international clinical-stage biopharmaceutical company has a strong foothold in the biotechnology, health care, and pharmaceutical industries. With its research and development facilities and clinical operation centers in China and the United States, Adlai Nortye has positioned itself as a key player in the global fight against cancer. The company's dedication to oncology is evident through its robust pipeline, consisting of over 10 drug candidates developed through partnerships and internal discoveries. In September 29, 2023, Adlai Nortye secured a significant $40.00M Post-IPO Equity investment from Nippon Kayaku, signifying a strong vote of confidence from a reputable investor in the company's vision and potential. This investment not only underscores the company's trajectory in the biopharmaceutical sector but also highlights its attractiveness to strategic partners. Adlai Nortye's dedication to innovation and global impact positions it as an intriguing prospect for venture capital firms seeking to drive meaningful change in the oncology space.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$40.00M	2	Ruihe Capital, Nippon Kayaku	29 Sep 2023
Series D	$100.00M	7	Legend Star, SDIC Fund Management +5	13 Jul 2021
Series C	$100.00M	1	ICBC Asset Management	31 Aug 2020
Series B	$53.00M	-		26 Jun 2018
Series A	Undisclosed	-		01 Jan 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$40.00M

Ruihe Capital, Nippon Kayaku

29 Sep 2023

Series D

$100.00M

Legend Star, SDIC Fund Management +5

13 Jul 2021

Series C

$100.00M

ICBC Asset Management

31 Aug 2020

Series B

$53.00M

26 Jun 2018

Series A

Undisclosed

01 Jan 2016

FAQ About Adlai Nortye

Pioneering the future of oncology with innovative drug development across the globe.

Adlai Nortye was founded in 2016.

Adlai Nortye operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on oncology, drug development, biopharmaceutical and clinical-stage.

Adlai Nortye has approximately 51-200 employees.

Adlai Nortye has completed 5 funding rounds, raising a total of $293.00M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Adlai Nortye include Xynomic Pharma, EOC Pharma Group, Apollo Therapeutics, Aston Sci., Y-mAbs Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Adlai Nortye and Xynomic Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Adlai Nortye

Funding Rounds & Investors (5)

Adlai Nortye Alternatives & Competitors

FAQ About Adlai Nortye